Ranjit Kumar Sahoo

Learn More
The purpose of this study was to evaluate the efficacy and safety of a novel theranostic agent, 177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer (mCRPC). Thirty-one mCRPC patients with progressive disease despite second-line hormonal therapy and/or docetaxel chemotherapy were recruited for the study. All patients underwent(More)
INTRODUCTION The purpose of this study was to evaluate the effect of prognostic factors on the outcome of patients with MM after ASCT. PATIENTS AND METHODS We analyzed results of 170 consecutive patients (121 male and 49 female) of MM who underwent ASCT. Patients' median age was 52 years (range, 26-68 years). High dose melphalan (200 mg/m(2)) was used for(More)
Paraneoplastic neurological syndromes (PNSs) are commonly encountered with underlying malignant pathology. Though anti--neuronal antibodies play a major role in the diagnosis of the underlying malignant pathology but at many times it becomes inconclusive. As early detection of the primary cause and its treatment gives the best result in such situations,(More)
Extraskeletal osteosarcoma is a rare malignant soft tissue tumor. At open cholecystectomy performed for gallstones, a 45-year-old woman was found to have extraskeletal osteosarcoma on histopathological examination. 1 year after surgery, the patient is symptom free and all imaging studies are normal. After multidisciplinary discussion it was decided to give(More)
BACKGROUND Survival of myeloma patients has improved considerably in the past decade. However, limited data are available on their long-term outcome. We analysed the data of 225 consecutive patients who underwent autologous stem cell transplantation (ASCT) at our centre. METHODS Between April 1990 and December 2013, a total of 225 patients with multiple(More)
OBJECTIVE Lu-DKFZ-PSMA-617, a urea-based compound, binds to the extracellular domain of prostate-specific membrane antigen, thus providing an effective target for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Before its therapeutic use, it is necessary that the radiation dosimetry of this radiopharmaceutical be studied to(More)
Whether this neutropenia is a class effect of this drug or due to dose and schedule effect is not known. The recommended dose of palbociclib (125 mg/day orally for 3 weeks, followed by 1 week off) is derived from a very few phase, 1/2 studies resulting in limited information about tolerability. Hence, to confirm its relationship with neutropenia,(More)